Symposium: NAFLD management in 2018

 Metabolism, alcohol and toxicity
 Webcasted session

North 1
13 April 2018 14:00 - 15:30

NAFLD is currently the most prevalent chronic liver disease and its impact on health care resources is rapidly increasing. Despite the impressive effort in basic and clinical research, many knowledge gaps exist limiting the possibility to provide detailed evidence-based guidelines to shape clinical care. This symposium aims at providing an update anno 2018 on the knowledge on several key issues that are highly relevant for the clinicians taking care of NAFLD patients. Should we screen for NAFLD, who should be screened fand how can this be done? How far can we currently go along with the non-invasive diagnosis? What does “life style modification” mean, what’s the evidence and how can we achieve it? And what is currently available as a pharmacological treatment. The symposium hence focuses on the clinical evidence and its current applicability, with a short glimps into the near future. 


Case finding and screening in populations at risk: Where do we stand?
Manal Abdelmalek , United States
13 April 2018 14:00 - 14:20

Non-invasive techniques: Current role in diagnosis and follow-up
Jerome Boursier , France
13 April 2018 14:20 - 14:40

Life style intervention: What are the needs?
Kate Hallsworth , United Kingdom
13 April 2018 14:40 - 15:00

Pharmacological therapy: What to expect in the near future?
Sven Francque , Belgium
13 April 2018 15:00 - 15:20

13 April 2018 15:20 - 15:30